Cosmetics industry stakeholders are frustrated.
The FDA Safety and Landmark Advancements Act proposed in the US Senate, S. 4348, would dramatically overhaul federal cosmetics regulations,...
Cosmetics Industry Stakeholders Not Thrilled About Senate Reform Bill, And Why Should They Be?
Listen to this article
In HBW Insight’s conversations with industry advocates about legislation in the US Senate to reform US cosmetics regulations, frustrations with the process have been palpable. Stakeholders suggest that science and proportionality are taking back seats to politics and that concerns about costs to industry, which ultimately could be passed on to consumers, are not being taken seriously enough.
Explore how consumer health is evolving. On the go.
More from Legislation
• By
The gut’s microbiome will shape future medical advances, offering personalized therapies and prevention strategies for a wide range of diseases.
• By
P&G's FY2024 Q4 net sales were flat at $20.5bn, lower than consensus estimates, but the firm says its underlying business divisions are healthy and forecasts FY2025 sales up 2% to 4%, up 3% to 5% organically.
• By
Legislator education is key to checking state bills that overreach, says Ross, executive VP of government affairs at the Personal Care Products Council, discussing the rising tide of US state bills aimed at restricting ingredient use.
• By
FDA reminds companies which registered with agency solely to manufacture OTC sanitizers during COVID-19 public health emergency they will be subject to FY2025 OTC monograph user fees if they don’t delist and deregister as monograph drug manufacturers by 12 a.m. on 31 December.
More from Policy & Regulation
• By
With monographs@FDA portal down, agency moves to NextGen and extends comment period through 27 September for first OTC monograph change it proposed using its overhauled program other than 32 monographs finalizations required in 2020 legislation authorizing overhaul.
• By
OTC sales edged up at Italy's Recordati in the first half of 2024 as higher demand for GI products and supplements offset a weaker cold & flu season.
• By
P&G's FY2024 Q4 net sales were flat at $20.5bn, lower than consensus estimates, but the firm says its underlying business divisions are healthy and forecasts FY2025 sales up 2% to 4%, up 3% to 5% organically.